Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
BUSINESS
Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
Tokyo-based biotech Oncolys BioPharma has won key allies at Chugai Pharmaceutical for the development of its oncolytic virus telomelysin, with the two companies announcing their deal on April 8, which included the drug’s licensing as well as a capital tie-up…
To read the full story
Related Article
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
April 15, 2021
- Jiangsu Hengrui to Return Telomelysin’s China Rights to Oncolys
June 10, 2020
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief
February 4, 2020
- Oncolys to Receive 500 Million Yen from Chugai in Telomelysin Milestone
December 13, 2019
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
February 1, 2019
- Oncolys Licenses Oncolytic Virus Telomelysin to Hengrui in China
December 2, 2016
BUSINESS
- Ashraf Al-Ouf Named President of Bayer Yakuhin and Bayer Holding in Japan
August 8, 2025
- Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
- PeptiDream Probes Ex-COO over Unauthorized Provision of Reagents to Academia
August 8, 2025
- Kaken, Astria Ink Japan Deal for Navenibart for HAE Prophylaxis
August 8, 2025
- Ono, Seikagaku Finalize Japan Deal on Osteoarthritis Drug
August 8, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…